SY1: Share Buybacks And Dividend Policy Will Support Future Share Repricing

Analysts have adjusted the Symrise fair value estimate slightly lower to about €91.76 from roughly €92.82, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, alongside mixed but generally supportive recent price target moves from the Street.

Analyst Commentary

Bullish Takeaways

Goldman Sachs and other bullish analysts are signaling improving confidence in Symrise, which supports the idea that the current valuation is not stretched relative to their expectations.
The €100 price target from JPMorgan, even after an adjustment, still implies room for upside against the revised fair value estimate of about €91.76. This suggests that some analysts see further value if execution meets their assumptions.
Recent upgrades point to comfort with Symrise's ability to deliver on revenue and margin assumptions that underpin higher P/E multiples than more cautious peers might be using.
The raised price target around €81.20 from one firm indicates that even more neutral voices see enough support in the fundamentals to justify fine tuning their models upward rather than stepping back.

Bearish Takeaways

Some bearish analysts are keeping Hold ratings, which points to hesitation around paying too much for execution that still has to be proven, especially relative to the trimmed fair value estimate.
The reduction in the price target to €100 from €105 at JPMorgan, despite an Overweight rating, underscores that even optimistic analysts see limits to how far the valuation can stretch without clearer evidence on growth and margins.
The moderate nature of recent target changes, both higher and lower, suggests that analysts are cautious about assuming large improvements in profitability or P/E. This may cap how aggressively they are willing to mark up their models.
Ongoing reliance on relatively rich future P/E assumptions in some research leaves room for disappointment if revenue and margin outcomes do not match the more optimistic forecasts embedded in those targets.

What's in the News

Symrise set an annual dividend of €1.25 per share, with payment scheduled for May 11, 2026, ex date on May 7, 2026, and record date on May 8, 2026 (Key Developments).
The company plans to start share repurchases on February 2, 2026, under an authorization that allows buying back up to 13,977,205 shares, equal to 10% of issued share capital, valid until May 19, 2030 (Key Developments).
On January 12, 2026, Symrise announced a share repurchase program of €400 million, with the primary aim to redeem shares and reduce registered share capital, with purchases running from February 1 to October 31, 2026 (Key Developments).
Repurchase pricing will be linked to the Xetra opening auction, with a 5% variance limit around the opening auction price for stock exchange transactions and a 10% variance band around the recent 3 day average price for public purchase offers (Key Developments).

Valuation Changes

Fair Value: trimmed slightly from €92.82 to about €91.76 per share, a move of roughly 1%.
Discount Rate: nudged higher from about 5.73% to about 5.77%, a small adjustment to the risk input in the model.
Revenue Growth: edged up from roughly 3.98% to about 4.00%, a minor change in the long term euro revenue growth assumption.
Net Profit Margin: adjusted marginally lower from about 11.71% to about 11.70%, implying a very small shift in expected profitability.
Future P/E: moved down slightly from about 23.68x to about 23.43x, indicating a modestly lower valuation multiple assumption.

0 views

Key Takeaways

Operational efficiency initiatives, portfolio optimization, and disciplined cost controls are driving lasting margin improvement, free cash flow, and overall earnings quality.
Focus on R&D, natural ingredient innovation, and emerging market expansion positions Symrise for premium pricing and resilient, above-market long-term growth.
Competitive pressures, macroeconomic headwinds, and weaker end-market demand are likely to constrain growth and margins despite cost-saving and transformation initiatives.

Catalysts

About Symrise

Operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America.What are the underlying business or industry changes driving this perspective?

Symrise is executing a multi-year transformation focused on operational efficiency, portfolio optimization, and disciplined cost management, which is already yielding substantial margin improvements (notably, a gross margin increase of 250 bps and an EBITDA margin uplift), laying the groundwork for structurally higher net margins and improved earnings compounding.
Ongoing and targeted cost savings measures (€40 million in 2025, following €50 million in 2024) and optimized procurement strategies are expected to deliver sustainable operating leverage and support both margin expansion and stronger free cash flow generation.
Symrise's continued investment in R&D, innovation, and proprietary launches in natural and functional ingredients targets growing consumer demand for health-conscious, sustainable, and science-backed solutions, positioning the firm to capture secular volume growth and premium pricing, directly benefiting revenue and margins over the long term.
Expansion in high-growth emerging markets such as Latin America and Asia Pacific, alongside a proactive approach to portfolio management (divestments of non-core, lower-margin businesses), is expected to boost top-line growth, increase geographic diversification, and strengthen resilience against developed market stagnation.
As global customers increasingly outsource ingredient complexity due to rising demand for product innovation, personalization, and regulatory-driven reformulations, Symrise's specialty expertise and enhanced customer relationships are likely to translate into above-market revenue growth and defend against commoditization risks.

Symrise Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Symrise's revenue will grow by 4.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 5.1% today to 11.7% in 3 years time.
Analysts expect earnings to reach €648.7 million (and earnings per share of €4.74) by about April 2029, up from €249.3 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.4x on those 2029 earnings, down from 41.0x today. This future PE is lower than the current PE for the GB Chemicals industry at 27.6x.
Analysts expect the number of shares outstanding to grow by 0.08% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.77%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company is experiencing a normalization and slowdown in several key end markets, notably in Pet Nutrition and Pet Food, due to cautious consumer sentiment and price pressures, which may dampen segment revenue growth and compress net margins in the near to mid-term.
Management has revised down its organic growth guidance for 2025 from 5%-7% to 2%-5%, reflecting a more challenging global demand environment and slower market growth expectations; sustained slower growth could limit revenue and earnings upside potential.
Increasing regional and local competition, particularly in pet and nutrition markets, as well as pressure from private label brands, could erode Symrise's pricing power and market share, resulting in pressured revenues and potentially lower net margins.
Currency headwinds and macroeconomic uncertainty in regions like North America have resulted in negative FX impacts and weaker organic growth, highlighting ongoing exposure to global economic and political volatility that could impact overall earnings and free cash flow.
The company's transformation and cost savings initiatives, while driving margin improvement, also require reinvestment into digitalization, R&D, and organizational change, which introduces execution risk and could put pressure on near-term margins if savings do not sufficiently offset increased investment or if efficiency gains are not fully realized.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €91.76 for Symrise based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €110.0, and the most bearish reporting a price target of just €70.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €5.5 billion, earnings will come to €648.7 million, and it would be trading on a PE ratio of 23.4x, assuming you use a discount rate of 5.8%.
Given the current share price of €73.98, the analyst price target of €91.76 is 19.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Symrise?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Elevated Sector Risks Will Shape Industry Outlook Amid Global Expansion